Noa Therapeutics is a preclinical biotech company leveraging a systems biology approach to accelerate design of tailored multimodal therapeutics for complex inflammatory diseases. With discrete expertise in dermal therapeutics, Noa is advancing a first-use case in Atopic Dermatitis. Noa’s lead ID, NOA-101, simultaneously addresses three constructive targets to address persistent unmet needs to displace multiple major players within the $5.0B, 10.1% CAGR, US Market; paving the way for pipeline expansion into >$70B inflammatory disease markets.
Intellectual Property
Fundraising
Are you developing and/or redesigning new green products, services, processes, and technologies that reduce environmental impact?
The i.d.e.a.™ Fund program focuses on supporting a more sustainable economy while fostering an inclusive and equitable growth in southern Ontario. Find out if you’re eligible to access up to $20,000 in matching seed funding and 30 hours of expert mentorship.
Applications are open from June 16 to July 7, 2025.
